Life Sciences & Biotechnology
Title: | Repurposing of Umifenovir
against COVID-19 |
Area: | Life Sciences & Biotechnology, Pharmaceutical Sciences, COVID-19 Technology |
Focus Area: | Development of Repurposed Drugs for COVID-19 |
Company Transferred: | Medizest Pharmaceuticals Pvt. Ltd., Goa |
Developing Agency: | Central Drug Research Institute (CSIR-CDRI), Lucknow |
Technology Readiness Index: | Technology development |
| Website Link : | https://cdri.res.in/ |
Brief Description
Description : | An economical process technology has been developed using indigenously available key starting materials. CSIR-CDRI has received the permission from Central Drugs Standard Control Organization for conducting the Phase III clinical trial with Umifenovir entitled "Randomised, double blind, placebo controlled trial of efficacy, safety and tolerability of Antiviral drug Umifenovir vs standard care of therapy in non-severe COVID-19 patients.” |
Related Technologies